Clay Siegall founded Seattle Genetics, Inc. in 1998. It is a pharmaceuticals and biotechnology Corporation specializing in treatment for many various cancer diseases. Seattle Genetics, Inc. is located in Bothell, Washington’s Puget Sound area, and is Washington State’s largest biotech Corporation.
Their inaugural, commercialized drug, Adcetris, is being considered for use in more cancer treatments than the current 70 various lymphoma types undergoing trials. Particularly, Seattle Genetics is directing an advanced trial that will utilize Adcetris as an up-front treatment for newly diagnosed or otherwise untreated patients with Hodgkin Lymphoma.
Adcetris’ main use, so far, is to combat lymphomas. It has brought in $226 million in sales in the U.S. and Canada in the previous year and is set to increase that amount, in 2016, to approximately $255 to $275 million. Takeda Pharmaceuticals, Seattle Genetics Partner, handles sales outside of Canada and the U.S. Antibody-based Adcetris is just the first of 12 other drugs being developed by Seattle Genetics. One of these, referred to as 33A, is a drug for treatment of myeloid leukemia. They also have a breast cancer drug and two other drugs for the treatment of bladder cancer. They hope to get these new drugs into use this year.
Seattle Genetics, Inc. also plans a large-scale hiring event. Though it already employs more than 800 people, there are plans this year to hire an additional 100 employees here and another 20 in their Switzerland office. Most new hires will be positioned in “operations” rather than research.
Clay Siegall earned BS and Zoology Degrees at the University of Maryland and a Ph.D. and Genetics degree at the George Washington University, where he was Alumnus of The Year for Natural Science, Math, and Computer. Mr. Siegall has been the Co-Founder, President, CEO, and Chairman of the Board of Seattle Genetics, Inc., since 1998.
Mr. Siegall has also been on Alder Biopharmaceuticals Board of Directors since 2006, and a Board Member of Mirna Therapeutics since 2013. He is also on the Board of Directors at Ultragenyx Pharmaceuticals, which markets new products for treating rare and extremely rare diseases, since 2014.